# A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)

> **NCT03474107** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 608 (actual)

## Conditions studied

- Ureteral Cancer
- Urothelial Cancer
- Bladder Cancer

## Interventions

- **DRUG:** Enfortumab Vedotin
- **DRUG:** Docetaxel
- **DRUG:** Vinflunine
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03474107
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-27
- **Primary completion:** 2020-07-15
- **Final completion:** 2025-11-27
- **Target enrollment:** 608 (ACTUAL)
- **Last updated:** 2026-01-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03474107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03474107, "A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03474107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*